Sun Pharmaceuticals Industries’ subsidiary has received US Food and Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI Liposome Injection USP 2mg/ml, packaged in 20mg/10ml and 50mg/25ml single use vials.
The generic Doxorubicin HCI Liposome Injection USP 2mg/ml is therapeutically equivalent to Doxil Liposome Injection 2mg/ml of Janssen Research and Development, LLC. Doxorubicin HCI Liposome Injection is used to treat patients with ovarian cancer that has progressed of recurred after platinum-based chemotherapy.
Sun Pharmaceuticals Industries is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.
